To develop novel therapies for aggressive thyroid cancers, we have synthesized a collection of histone deacetylase (HDAC) inhibitor analogs named AB1 to AB13, which have different linkers between a metal chelating group and a hydrophobic cap. The purpose of this study was to screen out the most effective compounds and evaluate the therapeutic efficacy. AB2, AB3 and AB10 demonstrated the lowest half-maximal inhibitory concentration (IC 50 ) values in one metastatic follicular and two anaplastic thyroid cancer cell lines. Treatment with each of the three ABs resulted in an increase in apoptosis markers, including cleaved poly adenosine diphosphate ribose polymerase (PARP) and cleaved caspase 3. Additionally, the expression of cell-cycle regulatory proteins p21 WAF1 and p27 Kip1 increased with the treatment of ABs while cyclin D1 decreased. Furthermore, AB2, AB3 and AB10 were able to induce thyrocyte-specific genes in the three thyroid cancer cell lines indicated by increased expression levels of sodium iodide symporter, paired box gene 8, thyroid transcription factor 1 (TTF1), TTF2 and thyroid-stimulating hormone receptors. AB2, AB3 and AB10 suppress thyroid cancer cell growth via cell-cycle arrest and apoptosis. They also induce cell re-differentiation, which could make aggressive cancer cells more susceptible to radioactive iodine therapy.
INTRODUCTION
Thyroid cancer is the most common endocrine malignancy and the most rapidly increasing cancer in the United States. 1 Although the overall survival for many thyroid cancer patients is favorable with recommended treatment of surgical removal of the tumors and post-operative radioactive iodine ablation, 2 aggressive thyroid cancer types, including anaplastic thyroid carcinoma and advanced papillary or follicular carcinoma, are still a clinical challenge. 3 Aggressive thyroid cancers often manifest with metastatic and/or recurrent disease, for which surgical resection remains largely palliative. 4 In addition, these thyroid cancers usually lose thyroid-specific gene expression due to their undifferentiated or poorly differentiated phenotypes, which impair the capacity for concentrating iodine. The conventional treatments, including radioactive iodine ablation, are therefore not effective for aggressive thyroid cancer patients. 5, 6 Currently, there are limited effective systemic therapies for these patients and novel targeted treatment modalities are desperately needed.
Histone deacetylase (HDAC) has been discovered as potential therapeutic targets for the treatment of human malignancies. HDACs are an important family of enzymes which, by working together with the histone acetyltransferases, control the balance between the acetylated and deacetylated states of chromatin. [7] [8] [9] Alterations in HDAC activity affect epigenetic regulatory mechanism for chromatin structure and gene expression thus contribute to diseases including neoplastic transformations. 10 To target this dysregulated epigenetic control, HDAC inhibitors have garnered interest as promising antineoplastic agents. HDAC inhibitors are capable of inducing apoptosis, cell-cycle arrest and differentiation in various cancer cells. 11 In thyroid cancers, many HDAC inhibitors, including valproic acid, suberoylanilide hydroxamic acid and Thailandepsin A, have shown to induce growth arrest and caspase-mediated apoptosis. [12] [13] [14] HDAC inhibition also suppresses cell migration and invasion in papillary, follicular and anaplastic cancer lines. 15, 16 Furthermore, it has been reported that some HDAC inhibitors like valproic acid can enhance the sensitivity to doxorubicin in anaplastic thyroid cancer cells. 17 However, there are currently no HDAC inhibitors approved by US FDA to treat aggressive thyroid cancers, which evoke the need to develop novel compounds.
Therefore, we synthesized a group of analogs targeting HDACs named AB1 to AB13. These analogs (ABs) share a conserved hydroxamic acid metal chelating group that binds to the zinc moiety on HDACs and a conserved anisole hydrophobic cap. They have distinct linkers between the metal chelating group and the hydrophobic cap. 18 The purpose of this study was to screen out the most effective compounds using multiple aggressive thyroid cancer cell lines and evaluate the therapeutic efficacy on cell proliferation, apoptosis and differentiation.
MATERIALS AND METHODS

Cell culture and reagents
Three human-derived aggressive thyroid cancer cell lines FTC236 (metastatic follicular thyroid cancer), HTh7 (anaplastic thyroid cancer) and 8505C (anaplastic thyroid cancer) were used for the current study.
HTh7 was kindly provided by Dr Rebecca Schweppe at University of Colorado (Denver, CO). Both FTC236 and 8505C were purchased from Sigma-Aldrich (St Louis, MO). All three cell lines were authenticated and confirmed with their unique identity by DNA profiling. 19 The cell lines were all tested negative for mycoplasma contamination. FTC236 cells were maintained in DMEM: F-12 medium with 10% fetal bovine serum, 10μg ml − 1 insulin and 0.01 U ml − 1 thyroid-stimulating hormone (TSH) (Sigma-Aldrich). HTh7 cells were maintained in RPMI-1640 medium (Invitrogen Life Technologies, Carlsbad, CA) with 10% fetal bovine serum. 8505C cell was maintained in EMEM medium (Sigma-Aldrich) with 10% fetal bovine serum and 1% non-essential amino acids (Sigma-Aldrich). All cells lines were grown in a humidified environment of 5% CO 2 at 37°C. AB1-AB13 analogs were synthesized by Dr Weiping Tang (Department of Chemistry, UW-Madison), dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich), and stored at − 20°C in 10 mM stock solution.
Cellular proliferation assay FTC236, HTh7 and 8505C were treated with AB1-AB13 in varying doses to determine the half-maximal inhibitory concentration (IC 50 ) of each compound using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Each cell line was plated in quadruplicate on 96-well plates at a density of 5000 cells per well. After incubation overnight to allow cell attachment, treatment medium with different concentrations (0-64 μM) of ABs was added in serial dilutions. Cell viability was measured 72 h after treatment. On the day of measurement, treatment medium was removed before cells were incubated at standard conditions in 25 μL of serum-free RPMI-1640 containing 0.5 mg ml − 1 MTT for 3 ½ hours. To dissolve the MTT formazan, 75 μL of DMSO was added to each well and mixed thoroughly. Absorbance was measured at 540 nm using a spectrophotometer (μQuant; Bio-Tek Instruments, Winooski, VT). The IC 50 value was calculated by GraphPad Prism 6 (GraphPad Software, La Jolla, CA).
Western blot analysis
Thyroid cancer cells were treated with selected concentrations of ABs for 2 days before protein lysates were isolated as previously described. 20 Protein concentrations were quantified by BCA Protein Assay Kit (Thermo Scientific, Waltham, MA) following the manufacturer's instructions. Denatured protein samples were resolved by 4-15% Criterion TGX gradient gel (Bio-Rad Laboratories, Hercules, CA) electrophoresis and then transferred onto nitrocellulose membranes (Bio-Rad Laboratories). Protein-bound membranes were blocked in 5% nonfat milk solution and incubated with appropriate primary antibodies overnight at 4°C. Primary antibodies were diluted as follows: 1:3000 for cleaved poly adenosine diphosphate ribose polymerase (PARP) and p21 WAF1 (Cell Signaling Technology, Beverly, MA; #9546 and #2946, respectively); 1:2000 for glyceraldehyde 3-phosphate dehydrogenase (Santa Cruz Biotechnology, Dallas, TX; sc-25778); 1:1000 for p27 (Santa Cruz Biotechnology; sc-1641), cyclin D1, β-Actin and cleaved caspase 3 (Cell Signaling Technology; #2922, #4970 and #9662, respectively). The next day, membranes were washed and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-rabbit/mouse secondary antibodies (Cell Signaling). Immunoreactive protein bands were detected by Immunstar (Bio-Rad Laboratories), SuperSignal West Pico or SuperSignal West Femto reagents (Pierce Biotechnology, Rockford, IL).
Quantitative real-time PCR
Total RNA was isolated from cultured cells 2 days after ABs treatment using an RNeasy Plus Mini kit (Qiagen, Valencia, VA). Total RNA concentration was determined by NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE). Complementary DNA was synthesized from 2 μg of total RNA using iScript cDNA Synthesis Kit (Bio-Rad Laboratories).
The quantitative real-time PCR was performed in triplicate on MyiQ Thermal Cycler (Bio-Rad Laboratories). The sequences for the PCR primers for the genes of interest are listed in Supplementary Table S1 . Target gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase levels in respective samples as an internal standard, and the comparative cycle threshold (ΔCt) method was used to calculate relative expression levels of target genes.
Biochemical assay for inhibitory effects on selective HDACs
The HDAC-Glo I/II assay kit (G6420) was provided by Promega Corporation (Madison, WI). Human recombinant C-ter-GST-HDAC 1 (H83-30G) and C-ter-HIS-HDAC 8 (H90-30H) were purchased from SignalChem (Richmond, BC, Canada). Human recombinant C-ter-HIS-HDAC 2 (50002) and N-ter-GST-HDAC 6 (50006) were purchased from BPS Bioscience (San Diego, CA). Human recombinant HDAC 3/NCOR1 complex (BML-SE515) and C-ter-HIS-HDAC 10 (BML-SE559) were purchased from Enzo Life Sciences (Farmingdale, NY). The HDAC-Glo I/II assay was used as previously described 21 to determine IC 50 values. Briefly, a 15-point threefold serial dilution of compounds AB2, AB3 or AB10 was performed at a 100 × concentration in 100% DMSO in a master 96-well plate. A 5-μL aliquot of this master 100 × / 100% DMSO titration series was added to 245 μL of HDAC-Glo I/II assay buffer to generate a 2 × concentrated, 2% DMSO master intermediate titration series of compounds AB3, AB2 or AB10 in a 96-well plate. From this master intermediate titration series, 5 μL replicates (n = 4) were transferred to a white, low-volume, round-bottom, non-binding surface 384-well assay plate (Corning 3673, Lowell, MA). An equal volume (5 μL) of the appropriate 2 × concentrated human recombinant HDAC enzyme was then added in HDAC-Glo I/II assay buffer. The 10-μL human recombinant HDAC enzyme/compound inhibitor (AB3, AB2 or AB10) mixes were allowed to pre-incubate for 20-30 min at room temperature. Following this preincubation, an equal volume (10 μL) addition of HDAC-Glo I/II final detection reagent was added for a 20-μL final assay volume per well. After incubation at room temperature for 20 min to allow the reactions to reach steady state, luminescence was measured on a BMG CLARIOstar (BMG LABTECH, Ortenberg, Germany).
Statistical analysis
The data were analyzed using GraphPad Prism 6 and Excel (Microsoft, Redmond, WA). Unless specifically noted, continuous data were presented as mean ± s.e.m. Student's t-test (two-sided) and one-way ANOVA were used to evaluate differences between two groups and among multiple groups, respectively. When necessary, data were transformed to better meet the assumptions of ANOVA. Po0.05 was considered as statistically significant.
RESULTS
Screening ABs by IC 50 in aggressive thyroid cancer cells
To screen for the effective analogs based on their growth inhibitory potency, MTT assay was carried out to measure cell viability of three thyroid cancer cell lines (FTC236, HTh7 and 8505C) 72 h after ABs treatment of different concentrations up to 64 μM. Among all the analogs, AB1, AB4, AB5, AB6 and AB13 (Figures 1a, d-f and m, respectively) showed very limited cytotoxicity effects in all three cell lines. The IC 50 values of these five compounds were above 50 μM in FTC236 and HTh7 (Table 1) . For 8505C cells, the IC 50 of AB1, AB5 and AB6 also exceeded 50 μM while AB4 and AB13 demonstrated to be among the least effective analogs with IC 50 of 44.3 and 38.1 μM, respectively. AB7, 8, 9, 11 Furthermore, cleaved PARP and cleaved caspase 3, both of which are pro-apoptotic markers in the execution phase of cell apoptosis, were greatly induced in a dose-dependent manner. This was observed in all cell lines treated with AB compounds compared with the control. In HTh7, the significant cleavages of PARP were observed at 10, 2.5 and 10 μM with AB2, AB3 and AB10 treatment, respectively (Figure 3a) . In 8505C, 20 μM of AB2 caused a noticeable induction of cleaved PARP while 10 μM of AB3 or AB10 resulted in the similar effect (Figure 3b ). Apoptosis were induced in FTC236 with the highest treatment concentration of each AB analog (Figure 3c ). Figure 1 . AB analogs show varying effects on the viability of human aggressive thyroid cancer cell lines HTh7, 8505C and FTC236. The cell lines were treated with AB1-AB13 (0-64 μM) for 72 h. Cell viability was measured by the MTT assay. The data were presented in mean percent viability ± s.e.m. AB1 (a), AB4 (d), AB5 (e), AB6 (f) and AB13 (m) showed very limited cytotoxicity. AB7 (g), AB8 (h), AB9 (i), AB11 (k) and AB12 (l) presented with moderate efficacy. AB2 (b), AB3 (c) and AB10 (j) showed the highest potency. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide. Thyroid-specific gene expression upregulated by AB2, AB3 and AB10 Since aggressive thyroid cancers are usually resistant to the radioactive iodine ablation due to de-differentiation, we further evaluated the efficacy of AB2, AB3 and AB10 on their ability to induce cell re-differentiation by the measurement of mRNA levels of thyroid-specific genes including sodium iodide symporter (NIS), paired box gene 8 (PAX8), thyroid transcription factor 1 (TTF1), TTF2 and TSH receptors (TSHR). These genes are usually downregulated in aggressive, radioactive iodine-resistant cells. AB2, AB3 and AB10 significantly induced NIS mRNA expression in all of the cell lines (Figures 4a-c) . AB2 increased NIS mRNA expression by 3.6, 3.7 and 7.0 folds in HTh7, 8505C and FTC236, respectively. AB3 treatment resulted in 15.7-, 64.4and 5.3-fold induction of NIS expression in the above three cell lines, respectively. Similarly, NIS levels were significantly elevated by AB10 treatment. Furthermore, TSHR expression increased significantly in HTh7 with all the ABs treatment, in 8505C treated with AB3 and AB10, and in FTC236 treated with AB2 and AB3. Additionally, the ABs had varying effects on mRNA expression levels of PAX8, TTF1 and TTF2. These transcription factors bind to the promoter regions of genes that encode proteins critical for thyroid hormone synthesis, such as the NIS and TSHR. 22 AB2, AB3 and AB10 significantly increased the mRNA expression of PAX8 and TTF2, but not TTF1, in HTh7 (Figure 4a ). In FTC236, the ABs significantly increased the mRNA expression of TTF1, but had a limited effect on PAX8 and TTF2 (Figure 4c ). Interestingly, 8505C did not show any increase in PAX8, TTF1 and TTF2 mRNA levels after the treatment with the ABs (Figure 4b ).
Inhibitory effects on class I and class II HDACs
To assess the inhibitory activity and selectivity of AB2, AB3 and AB10 to specific HDAC isoenzymes, we used the HDAC-Glo I/II luminescent assay (Promega) that measures the relative activity of HDAC class I and IIb enzymes. We first determined the optimal concentration of purified human recombinant HDACs to use per reaction. The optimal concentrations of the listed HDAC isoenzymes were in the lower end of the linear portion of the enzyme titration assay and concentrations were also chosen so all HDAC isoforms gave similar luminescent signal (relative luminescence unit) output. Next, we determined the IC 50 of AB2, AB3 and (Figures 5a-c) . AB3 revealed the highest inhibitory effects among the three AB analogs (Figure 5b ). It was more selective for HDACs 1, 2 and 3 with IC 50 of 4.3, 6.0 and 2.4 nM, respectively. The compound AB2 (Figure 5a ) was slightly less potent than AB3, but still showed good potency. Similar to AB3, AB2 demonstrated stronger selectivity toward HDACs 1, 2 and 3 (IC 50 28.6, 28.4 and 8.4 nM, respectively) versus HDACs 6, 8 and 10 (IC 50 298.3, 149.7 and 53.19 nM, respectively). The compound AB10 was a less potent Class I/II HDAC inhibitor than AB2 and AB3 according to this biochemical assay (Figure 5c ). It inhibited all HDAC isoforms at the doses ranging between 1.2 and 2.5 μM.
DISCUSSION
Aggressive thyroid cancers including the anaplastic thyroid cancer and some metastatic follicular thyroid cancers are still clinical challenging, emphasizing the need for new treatment strategies. 23 Anaplastic thyroid cancer (ATC) represents 1-2% of all thyroid cancers, but account for over half of thyroid cancer-related deaths. 24, 25 It is characterized by lacking of differentiation, aggressive local invasion and common distant metastases. All patients with ATC are classified as having a stage IV disease. The prognosis of ATC is extremely dismal with the mean survival time of less than 6 months following diagnosis 26 and 5-year survival rate of 0-25%. 24 Similarly, while well-differentiated thyroid cancers are highly curable with thyroidectomy and radioactive iodine ablation, approximately 20% present a more aggressive phenotype of distant metastasis or recurrence associated with increased mortality. 6, 27 Approximately 45% of patients with recurrence died of the disease, among which 75% died within 10 years of the detection of recurrence. 7 Additionally, 20-30% of patients with recurrent or metastatic differentiated thyroid cancers do not concentrate radioactive iodine, resulting in decreased survival. 28, 29 Recently, HDAC inhibitors have emerged as a class of promising compounds for targeted therapy to combat aggressive thyroid cancers. In the current study, we evaluated the drug efficacy of novel synthetic analogs AB1-AB13 that inhibit HDAC. Among the 13 candidates, AB2, AB3 and AB10 were selected for further assessment based on their most potent ability to reduce cell growth in multiple aggressive thyroid cancer cell lines. More important, the selected drugs were capable of inducing the expression of thyrocyte-specific differentiation markers.
The treatments with AB2, AB3 and AB10 induced growth inhibition by both apoptosis and cell-cycle arrest in the aggressive thyroid cancer cell lines in a dose-dependent manner. The AB treatments resulted in the cleavage of caspase-3, an apoptotic marker involved in the execution phase of both the intrinsic and extrinsic apoptotic pathway, 30 and the cleavage of PARP, a protein involved in DNA repair signaling and apoptosis. 31 Additionally, the ABs increased the levels of p21 WAF1 and p27 Kip1 which can bind to all CDK/cyclin complexes to inhibit their activity at multiple checkpoints in the cell cycle. 32 At the same time, ABs also decreased the levels of cyclin D1, a cell-cycle regulator that promotes the G1-S transition. 33 The overexpression and dysregulation of cyclin D1 have been implicated in many different types of cancers. 34 These results were consistent with previous studies that examined the effect of other HDAC inhibitors on many different types of malignancies 35 including thyroid cancers, [12] [13] [14] which suggests that AB compounds induce growth inhibition with a similar mechanism. We further characterized anti-HDACs activity of each AB analog. Both AB2 and AB3 demonstrated a strong selectivity on Class I HDACs including HDACs 1, 2 and 3. AB10 was able to inhibit both Class I and Class IIb HDACs but with a much higher drug concentration. The genetic knockdown of individual HDACs, most notably HDAC 1, 2, 3 and 6, in a variety of tumor types such as colon, breast and lung has been shown to induce apoptosis and cell-cycle arrest. 36 Thus, our data further implicate HDAC activity as a key mediator of cancer cell proliferation and survival capacity during the treatment with AB compounds.
Radioactive iodide is widely used for the diagnosis and the treatment of thyroid diseases. However, ATC and many metastatic FTC that do not express NIS fail to concentrate radioactive iodide sufficiently to achieve therapeutic effects. Other treatment options such as surgical removal of the tumors, external radiation and chemotherapy are largely unsuccessful. 37 In this study, we showed that the treatment of the aggressive thyroid cancer cells with the most potent ABs induced the expression levels of PAX8, TTF1, TTF2, TSHR and NIS in varying degrees, which can make the cancer more susceptible to radioactive iodide therapy possibly in combination with TSH. This is similar as other HDAC inhibitors Novel HDAC inhibitors on thyroid cancer S Jang et al such as depsipeptide, 38 valproic acid, 39, 40 trichostatin A 41 and suberoylanilide hydroxamic acid, 40 which have been shown to induce NIS expression in various thyroid cancers including ATC and FTC. The AB analogs may induce differentiation in the different aggressive thyroid cancer cell lines by separate mechanisms. One of the possible mechanisms of NIS induction is through the upregulation of TTF1 and PAX8, both of which are able to bind to the promoter or enhancer region of the NIS. 42 Previous studies have reported that undifferentiated thyroid cancers express very low, sometimes undetectable, basal level of PAX8 and TTF1 compared with the more differentiated subtypes. 19 In HTh7, the AB treatments resulted in the significant induction of PAX8. On the other hand, TTF1, but not PAX8, was significantly induced in FTC236 cells after the drug treatment. Previous studies also reported varying patterns of thyroid-specific genes after different HDAC inhibitor treatments. Suberoylanilide hydroxamic acid and valproic acid induced the expression of PAX8, but not TTF1, in an ATC cell line. 40 Depsipeptide induced the expression of NIS via the upregulation of TTF1 but not via PAX8. 43 Interestingly, in our study, the ABs robustly induced the mRNA expression levels of NIS in 8505C cell lines without the upregulation of TTF1, TTF2 or PAX8. This may reflect a difference in NIS induction mechanism between 8505C, which harbors the BRAF V600E mutation, and BRAF V600E wild-type cell lines such as HTh7 and FTC236. 19 The most commonly seen mutation in thyroid cancer is the BRAF V600E, 44 with a prevalence only second to that of melanoma in multiple cancers that have reported the mutation. 45 BRAF V600E mutation is detected in about 25% of ATC, and it is associated with increased aggressiveness including increased mortality, higher rates of recurrence, and resistance to radioactive iodide ablation from the lack of NIS and other thyrocyte-specific genes in differentiated thyroid cancers. 46 A recent study demonstrated that BRAF V600E leads to deacetylation by HDACs of multiple critical promoter regions on the NIS gene, which deregulates the binding of key transcriptional factors and consequently suppresses NIS expression. 47 In this current study, the AB treatments could have inhibited HDACs, which would lead to the maintenance of the acetylation status of the NIS promoter region in 8505C, prompting its induction despite the low levels of PAX8 and TTF1.
In summary, novel synthetic HDAC inhibitors AB2, AB3 and AB10 suppress thyroid cancer cell growth via cell-cycle arrest and apoptosis. The differences in structures of the AB analogs may shed light on more efficient future drug design. They also induce cell re-differentiation that could make aggressive thyroid cancer cells more susceptible to radioactive iodine therapy. Therefore, these compounds warrant further investigation for patients with aggressive thyroid cancers. 
